CoChat

Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells

Song, Qiaoling, Sun, Xiaoxiao, Guo, Hui, Yu, Qiang · 2017 · Oncotarget
Cited by 18

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.14009

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 33

  1. Schlessinger, 2010, Cell signaling by receptor tyrosine kinases, Cell, 141, 1117, 10.1016/j.cell.2010.06.011 · DOI · Paper page
  2. Rebai, 2011, Receptor tyrosine kinases: from biology to pathology, J Recept Signal Transduct Res, 31, 387, 10.3109/10799893.2011.625425 · DOI
  3. Morrison, 2012, Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy, Genes Dev, 26, 641, 10.1101/gad.186965.112 · DOI · Paper page
  4. Kholodenko, 2013, Complexity of receptor tyrosine kinase signal processing, Cold Spring Harb Perspect Biol, 5, a009043, 10.1101/cshperspect.a009043 · DOI
  5. Lane, 2005, ERBB receptors and cancer: the complexity of targeted inhibitors, Nat Rev Cancer, 5, 341, 10.1038/nrc1609 · DOI · Paper page
  6. Clark, 2000, The importance of being K-Ras, Cell Signal, 12, 425, 10.1016/S0898-6568(00)00084-X · DOI
  7. Sawyers, 2002, The phosphatidylinositol 3-Kinase AKT pathway in human cancer, Nat Rev Cancer, 2, 489, 10.1038/nrc839 · DOI · Paper page
  8. Mozzillo, 2012, The role of BRAF V600 mutation in melanoma, J Transl Med, 10, 85, 10.1186/1479-5876-10-85 · DOI · Paper page
  9. Clausen, 2015, FDA-approved small-molecule kinase inhibitors, Trends Pharmacol Sci, 36, 422, 10.1016/j.tips.2015.04.005 · DOI · Paper page
  10. Geng, 2014, Molecularly targeted cancer therapy: some lessons from the past decade, Trends Pharmacol Sci, 35, 41, 10.1016/j.tips.2013.11.004 · DOI · Paper page
  11. Hojjat-Farsangi, 2014, Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies, Int J Mol Sci, 15, 13768, 10.3390/ijms150813768 · DOI · Paper page
  12. Hardingham, 2014, KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model, Gastrointest Cancer Res, 7, 23
  13. Carvajal, 2016, Treatment of Uveal Melanoma, Cancer Treat Res, 167, 281, 10.1007/978-3-319-22539-5_12 · doi:10.1007/978-3-319-22539-5_12
  14. Settleman, 2008, Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma, Cancer Res, 68, 4853, 10.1158/0008-5472.CAN-07-6787 · DOI · Paper page
  15. Lukacs, 2014, Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors, Cancer Cell, 25, 697, 10.1016/j.ccr.2014.03.011 · DOI · Paper page
  16. Weber, 2016, Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas, Oncotarget, 7, 2734, 10.18632/oncotarget.6548 · DOI
  17. Fakih, 2015, Metastatic colorectal cancer: current state and future directions, J Clin Oncol, 33, 1809, 10.1200/JCO.2014.59.7633 · DOI · Paper page
  18. Jemal, 2016, Global Cancer Incidence and Mortality Rates and Trends—An Update, Cancer Epidemiol Biomarkers Prev, 25, 16, 10.1158/1055-9965.EPI-15-0578 · DOI · Paper page
  19. Bray, 2015, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int J Cancer, 136, E359, 10.1002/ijc.29210 · DOI · Paper page
  20. Schilsky, 2016, Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015, J Clin Oncol, 34, 179, 10.1200/JCO.2015.63.9674 · DOI · Paper page
  21. De, 2015, COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Res, 43, D805, 10.1093/nar/gku1075 · DOI · Paper page
  22. Yan, 2009, Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor, Cancer Research, 69, DDT01
  23. Gilmer, 2001, The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo, Mol Cancer Ther, 1, 85
  24. Ji, 2009, Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor, Future Med Chem, 1, 1153, 10.4155/fmc.09.89 · DOI · Paper page
  25. Comoglio, 2011, Ron kinase transphosphorylation sustains MET oncogene addiction, Cancer Res, 71, 1945, 10.1158/0008-5472.CAN-10-2100 · DOI
  26. Bardelli, 2014, RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells, Cell Rep, 8, 1475, 10.1016/j.celrep.2014.07.033 · DOI · Paper page
  27. Yamakawa, 2002, The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer cells, Clin Cancer Res, 8, 1957
  28. Alessi, 2011, Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1, Biochem J, 433, 357, 10.1042/bj20101732 · DOI
  29. Tavare, 2011, Akt signalling in health and disease, Cell Signal, 23, 1515, 10.1016/j.cellsig.2011.05.004 · DOI · Paper page
  30. Quon, 2001, Tyr(612) and Tyr(632) in human insulin receptor substrate-1 are important for full activation of insulin-stimulated phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose cells, Endocrinology, 142, 2833, 10.1210/endo.142.7.8283 · doi:10.1210/endo.142.7.8283 · Paper page
  31. Rosen, 2006, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt, Cancer Res, 66, 1500, 10.1158/0008-5472.CAN-05-2925 · DOI · Paper page
  32. Tsatsakis, 2015, Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review), International Journal of Oncology, 10.3892/ijo.2015.3306 · DOI · Paper page
  33. Lupinacci, 2014, Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers, Clin Cancer Res, 20, 5672, 10.1158/1078-0432.CCR-14-0868 · DOI · Paper page

Cited by

See all 18

Metadata

Authors
Song, Q., Sun, X., Guo, H., & Yu, Q.
Affiliations
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 201203 Shanghai, China
Venue
Oncotarget
Published
2016-12-17
Volume
8
Issue
3
Pages
5003-5015
ISSN
1949-2553
Cited by
18
References
9
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.